Payment overview · 2025
General Payments
$296.43
11 reported records · 9 companies
Healthcare provider profile · identity verified
Nathaniel S Franley, M.D
Allopathic & Osteopathic Physicians|Family Medicine · ERIE, PA · NPI 1992096549
Verified facts
What the public records show
CMS Open Payments records show Nathaniel S Franley, M.D received $296.43 in general payments during 2025 across 11 reported records.
Alexion Pharmaceuticals, Inc. accounted for 42.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.99 | 42.2% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $56.00 | 18.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.25 | 8.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.07 | 6.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.73 | 5.3% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $15.68 | 5.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.21 | 4.8% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.76 | 4.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.74 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.43 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| XCELL Normalized: xcell |
Device | Bioventus LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 666 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 90 |
| Lisinopril | Lisinopril | 328 | 106 |
| Metformin Hcl | Metformin Hcl | 319 | 89 |
| Losartan Potassium | Losartan Potassium | 305 | 88 |
| Omeprazole | Omeprazole | 293 | 91 |
| Gabapentin | Gabapentin | 250 | 69 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 240 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 67 |
| Glimepiride | Glimepiride | 176 | 48 |
| Furosemide | Furosemide | 173 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 49 |
| Trazodone Hcl | Trazodone Hcl | 127 | 41 |
| Warfarin Sodium | Warfarin Sodium | 125 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 47 |
| Jardiance | Empagliflozin | 121 | 31 |
| Eliquis | Apixaban | 118 | 22 |
| Simvastatin | Simvastatin | 113 | 35 |
| Potassium Chloride | Potassium Chloride | 108 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 30 |
| Ezetimibe | Ezetimibe | 95 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 28 |
| Allopurinol | Allopurinol | 85 | 28 |
| Carvedilol | Carvedilol | 82 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 25 |
| Prednisone | Prednisone | 76 | 35 |
| Atenolol | Atenolol | 75 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 43 |
| Celecoxib | Celecoxib | 72 | 25 |
| Spironolactone | Spironolactone | 65 | 19 |
| Alendronate Sodium | Alendronate Sodium | 61 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 16 |
| Famotidine | Famotidine | 56 | 12 |
| Azithromycin | Azithromycin | 52 | 43 |
| Finasteride | Finasteride | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Metformin Hcl Er | Metformin Hcl | 48 | 17 |
| Buspirone Hcl | Buspirone Hcl | 47 | 21 |
| Meloxicam | Meloxicam | 47 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 22 |
| Ozempic | Semaglutide | 45 | 11 |
| Sertraline Hcl | Sertraline Hcl | 44 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | 15 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 17 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | 11 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $296.43 · 11 records | Alexion Pharmaceuticals, Inc. | CONTRAVE, DUROLANE, EUFLEXXA, Iovera, MOUNJARO, ONZETRA XSAIL, UBRELVY, ULTOMIRIS, Wegovy, XCELL, XIFAXAN, ZEPBOUND, Zilretta | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error